Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma

Category Primary study
JournalFrontiers in Oncology
Year 2021
This article has no abstract
Epistemonikos ID: 27a002b02c60626824d86dde93192f2238e5fcf2
First added on: Nov 19, 2023